Dr. Frederick L. Flynt JR., M.D.
Hematology & Oncology (Hematology & Oncology Physician)
3320 Old Jefferson Rd Bldg 700
Athens, GA 30607
Who else practices at this address →
Jackson County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Mercer University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 730
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Mercer University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 59408
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Athens Regional Medical Center Athens, GA
- St Mary's Hospital Athens, GA
- Piedmont Newton Hospital Covington, GA
- Piedmont Walton Hospital Monroe, GA
- Morgan Medical Center Madison, GA
Medical groups
- University Cancer and Blood Center LLC (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 730
- Services billed
- 120,250
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 60,690 | 58 |
| Injection, pembrolizumab, 1 mg | 9,200 | 11 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 8,670 | 31 |
| Injection, denosumab, 1 mg | 5,100 | 34 |
| Injection, ferric derisomaltose, 10 mg | 3,600 | 31 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,952 | 55 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,685 | 508 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,664 | 532 |
| Insertion of needle into vein for collection of blood sample | 1,584 | 498 |
| Injection, ondansetron hydrochloride, per 1 mg | 960 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Procrit (epoetin alfa) | 216 |
| Anastrozole Other prescribers in Athens, GA | 155 |
| Eliquis (apixaban) Other prescribers in Athens, GA | 72 |
| Letrozole Other prescribers in Athens, GA | 69 |
| Prednisone Other prescribers in Athens, GA | 64 |
| Xarelto (rivaroxaban) Other prescribers in Athens, GA | 62 |
| Mirtazapine Other prescribers in Athens, GA | 62 |
| Hydroxyurea Other prescribers in Athens, GA | 49 |
| Neulasta Onpro (pegfilgrastim) | 46 |
| Abiraterone Acetate | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 38 companies reported 82 payments worth $1,795 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $214 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $130 |
| AbbVie Inc. | $109 |
| Janssen Biotech, Inc. | $98.98 |
| Pfizer Inc. | $91.00 |
| Gilead Sciences, Inc. | $83.18 |
| Array Biopharma Inc | $75.73 |
| EMD Serono, Inc. | $68.21 |
| Food and Beverage | $1,782 |
|---|---|
| Education | $13.04 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 3, 2025 | Education BRAFTOVI; MEKTOVI · ONCOLOGY · in-kind | $13.04 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $74,806 in research payments for these studies, mostly to the institutions running them.
- A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment Wi…
Genmab A/s - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Recruiting · NCT06568939
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.